26.03.2020 • News

NRDC Sues EPA Over Glyphosate Reapproval

NRDC Sues EPA Over Glyphosate Reapproval (c) Huntstock/Getty Images
NRDC Sues EPA Over Glyphosate Reapproval (c) Huntstock/Getty Images

US-based international environmental advocacy groups Natural Resources Defense Council  (NRDC) and the Pesticide Action Network pressure group (PAN) are suing the US Environmental Protection Agency (EPA)  over its reapproval of the widely used pesticide glyphosate.

By reapproving the use of the pesticide, the administration of US president Donald Trump is putting both public health and the environment – in particular pollinators – at risk and is once again ignoring science, the NGOs said.

 “By rubber-stamping the reapproval of glyphosate, the EPA ignored warnings from the scientific and environmental community,” Sylvia Fallon, senior director of NRDC’s wildlife division, commented.

The advocacy group has fought for nearly a decade to restrict the use of glyphosate, the active ingredient in the weed-killing product Roundup, for which it blames birth defects and non-Hodgkin’s lymphoma.

The latter disease also is at the center of the US lawsuits against Bayer, of which 43,000 are currently pending.

To address the looming biodiversity crisis faced by pollinators and thousands of other high-risk species, NRDC said it continues to advocate for effective, affordable, and non-chemical alternatives for controlling weeds.

 

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read